Inhibition of hepatitis B virus replication by the internal fragment of hepatitis B core protein

Virus Research

Volumn 150, Issue 1-2, 2010, Pages 129-134

  Han, Jinchao ^a   Pan, Xiaoben ^a   Gao, Yan ^a   Weil, Lai ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Antiviral peptide; Hepatitis B core protein; Hepatitis B virus; Nucleocapsid

Indexed keywords

COMPLEMENTARY DNA; CORE PROTEIN; HEPATITIS B CORE PROTEIN; LENTIVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA;

AMINO ACID SEQUENCE; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DNA SEQUENCE; DRUG MECHANISM; GENE EXPRESSION; GENETIC TRANSDUCTION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; SUPERNATANT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS ASSEMBLY; VIRUS INHIBITION; VIRUS LOAD; VIRUS NUCLEOCAPSID; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BIOLOGICAL PRODUCTS; CELL LINE; DNA, COMPLEMENTARY; DNA, VIRAL; GENETIC VECTORS; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; IMMUNOPRECIPITATION; LENTIVIRUS; OLIGOPEPTIDES; VIRUS ASSEMBLY; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 77952242656     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2010.03.005     Document Type: Article

References (38)

1. Alan M.R., Berriman J.A., et al. A structural model for maturation of the hepatitis B virus core. PNAS 2005, 102:1821-1826.
2. Trahtenherts A., Gal-Tanamy M., et al. Inhibition of hepatitis C virus RNA replicons by peptide aptamers. Antiviral Res. 2008, 72:195-205.
3. Adessi C., Soto C., et al. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr. Med. Chem. 2002, 16:963-978.
4. Dienstag J.L. Hepatitis B virus infection. N. Engl. J. Med. 2008, 359:1486-1500.
5. Guo H., Jiang D., et al. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J. Virol. 2009, 83:847-858.
6. Ghany M.G. Antiviral resistance and hepatitis B therapy. Hepatology 2009, 49:174-184.
7. Hermann Bultmann, James S.Busse, Curtis R.Brandt Modified FGF4 signal peptide inhibits entry of herpes simplex virus type 1. J. Virol. 2001, 6:2634-2645.
8. Hu J., Flores D., et al. Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function. J. Virol. 2004, 78:13122-21331.
9. Tsubery H., Mironchik M., et al. Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification. J. Biol. Chem. 2004, 279:38118-38124.
10. Conway J.F., Cheng N., Zlotnick A., et al. Localization of the N terminus of hepatitis B virus capsid protein by peptide-based difference mapping from cryoelectron microscopy. PNAS 1998, 95:14622-14627.
11. Connolly J.B. Lentiviruses in gene therapy clinic research. Gene Ther. 2002, 24:1730-1734.
12. Kock J., Nassal M., Deres K., et al. Hepatitis B virus nucleocapsids formed by carboxy-terminally mutated core proteins contain spliced viral genomes but lack full-size DNA. J. Virol. 2004, 78:13812-13818.
13. Karin Butz, Claudia Denk, et al. Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity. Oncogene 2001, 45:6579-6586.
14. König S., Beterams G., Nassal M. Mapping of homologous interaction sites in the hepatitis B virus core protein. J. Virol. 1998, 72:4997-5005.
15. Deres K., Schröder C.H., et al. Inhibition of Hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 2003, 299:893-896.
16. Naldini L., Blömer U., et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272:263-267.
17. Liaw Y.F., Leung N., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int. 2008, 2:263-283.
18. Sells M.A., Chen M.L., Acs G. Production of hepatitis B virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA. PNAS 1987, 84:1005-1009.
19. McGregor D.P. Discovering and improving novel peptide therapeutics. Curr. Opin. Pharmacol. 2008, 8:616-619.
20. Matsubara T., Sumi M., et al. Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library. J. Med. Chem. 2009, 52:4247-4256.
21. Mobley P.W., Barry J.A., et al. Membrane perturbing actions of HIV type 1 glycoprotein 41 domains are inhibited by helical C-peptides. AIDS Res. Hum. Retroviruses 2007, 23:224-242.
22. Newman M., Chua P.K., et al. Testing an electrostatic interaction hypothesis of hepatitis B virus capsid stability by using an in vitro capsid disassembly/reassembly system. J. Virol. 2009, 83:10616-10626.
23. Nguyen D.H., Hu J., et al. Reverse transcriptase- and RNA packaging signal-dependent incorporation of APOBEC3G into hepatitis B virus nucleocapsids. J. Virol. 2008, 82:6852-6861.
24. Schildgen O., Sirma H., Funk A., et al. Variant of hepatitis B virus with primary resistance to adefovir. N. Engl. J. Med. 2006, 352:2743-2746.
25. Suspene R., Guetard D., et al. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. PNAS 2005, 102:8321-8326.
26. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009, 49:103-111.
27. Wynne S.A., Crowther R.A., Leslie A.G.W. The crystal structure of the human hepatitis B virus capsid. Mol. Cell. 1999, 3:771-780.
28. Pogam S.L., Chua P.K., et al. Hepatitis B virus nucleocapsids formed by carboxy-terminally mutated core proteins contain spliced viral genomes but lack full-size DNA. J. Virol. 2005, 79:1871-1887.
29. Stray S.J., Bourne C.R., Punna S., et al. A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. PNAS 2005, 102:8138-8143.
30. Saccucci L., Crance, et al. Inhibition of vaccinia virus replication by peptide aptamers. Antiviral Res. 2009, 82:134-140.
31. Ta-Tung Yuan T.T-T., Sahu G.K., et al. The mechanism of an immature secretion phenotype of a highly frequent naturally occurring missense mutation at codon 97 of human hepatitis B virus core antigen. J. Virol. 1999, 73:5731-5740.
32. Tiscornia G., Singer O., Verma I.M. Production and purification of lentiviral vectors. Nat. Protoc. 2006, 1:241-245.
33. Terrault N.A. Benefits and risks of combination therapy for hepatitis B. Hepatology 2009, 49(5 Suppl):122-128.
34. von Weizsäcker F., Köck J., Wieland S., et al. Dominant negative mutants of the duck hepatitis B virus core protein interfere with RNA pregenome packaging and viral DNA synthesis. Hepatology 1999, 30:308-315.
35. Schellenberger V., Wang C-w., et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat. Biotechnol. 2009, 27:1186-1190.
36. Wadia J.S., Stan R.V., Dowdy S.F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 2004, 10:310-315.
37. Wang Y., Wei L., et al. In vitro resistance to interferon-alpha of hepatitis B virus with basic core promoter double mutation. Antiviral Res. 2007, 75:139-145.
38. Zlotnick A., Cheng N., Stahl S.J., et al. Localization of the C terminus of the assembly domain of hepatitis B virus capsid protein: implications for morphogenesis and organization of encapsidated RNA. PNAS 1997, 94:9556-9561.